Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2005-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Using a human pangenomic microarray, the researchers established expression profiles of nasal epithelial cells, collected by brushing of patients belonging to one of four distinct groups:

1. allergic rhinitis to dust mite (AR) isolated (n=12),
2. AR associated with bronchial hyperreactivity (n=12),
3. AR associated with asthma (n=14),
4. control (n=14).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)

NCT00960141

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients

NCT02461797

Allergic Rhinitis

COMPLETED NA

A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)

NCT00968149

Seasonal Allergic Rhinitis

COMPLETED PHASE3

The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)

NCT00092118

Rhinitis, Allergic, Perennial

COMPLETED PHASE3

Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)

NCT00963469

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Context: Asthma is the most frequent chronic disease in childhood. Allergic rhinitis has been described as a risk factor to develop asthma. The objective of the study was to evaluate the contribution of the respiratory epithelium to development of allergic rhinitis and asthma and to identify the molecular mechanisms driving rhinitis toward asthma.

Methods: Using a human pangenomic microarray, we established expression profiles of nasal epithelial cells, collected by brushing of patients belonging to one of four distinct children 2 to 18 years of age groups:

1. allergic rhinitis to dust mite (AR) isolated (n=12),
2. AR associated with bronchial hyperreactivity (n=12),
3. AR associated with asthma (n=14),
4. control (n=14).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Collection of nasal epithelial cells by brushing

Group Type OTHER

Collection of nasal epithelial cells

Intervention Type PROCEDURE

Collection of nasal epithelial cells by brushing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collection of nasal epithelial cells

Collection of nasal epithelial cells by brushing

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients:

* Patients between 6 and 17 years old
* Patients with allergic rhinitis

Witness:

* Patients between 6 and 17 years old
* Patients without allergic rhinitis and asthma